Effectiveness of ß-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia

Derek J. Williams, Kathryn M. Edwards, Wesley H. Self, Yuwei Zhu, Sandra Arnold, Jonathan Mccullers, Krow Ampofo, Andrew T. Pavia, Evan J. Anderson, Lauri A. Hicks, Anna M. Bramley, Seema Jain, Carlos G. Grijalva

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

IMPORTANCE ß-Lactam monotherapy and ß-lactam plus macrolide combination therapy are both common empirical treatment strategies for children hospitalized with pneumonia, but few studies have evaluated the effectiveness of these 2 treatment approaches. OBJECTIVE To compare the effectiveness of ß-lactam monotherapy vs ß-lactam plus macrolide combination therapy among a cohort of children hospitalized with pneumonia. DESIGN, SETTING, AND PARTICIPANTS We analyzed data from the Etiology of Pneumonia in the Community Study, a multicenter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted from January 1, 2010, to June 30, 2012, in 3 children’s hospitals in Nashville, Tennessee; Memphis, Tennessee; and Salt Lak City, Utah. The study included all children (up to 18 years of age) who were hospitalized with radiographically confirmed pneumonia and who received ß-lactam monotherapy or ß-lactam plus macrolide combination therapy. Data analysis was completed in April 2017. MAIN OUTCOMES AND MEASURES We defined the referent as ß-lactam monotherapy, including exclusive use of an oral or parenteral second- or third-generation cephalosporin, penicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate. Use of a ß-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) served as the comparison group. We modeled the association between these groups and patients’ length of stay using multivariable Cox proportional hazards regression. Covariates included demographic, clinical, and radiographic variables. We further evaluated length of stay in a cohort matched by propensity to receive combination therapy. Logistic regression was used to evaluate secondary outcomes in the unmatched cohort, including intensive care admission, rehospitalizations, and self-reported recovery at follow-up. RESULTS Our study included 1418 children (693 girls and 725 boys) with a median age of 27 months (interquartile range, 12-69 months). This cohort was 60.1% of the 2358 children enrolled in the Etiology of Pneumonia in the Community Study with radiographically confirmed pneumonia in the study period; 1019 (71.9%) received ß-lactam monotherapy and 399 (28.1%) received ß-lactam plus macrolide combination therapy. In the unmatched cohort, there was no statistically significant difference in length of hospital stay between children receiving ß-lactam monotherapy and combination therapy (median, 55 vs 59 hours; adjusted hazard ratio, 0.87; 95% CI, 0.74-1.01). The propensity-matched cohort (n = 560, 39.5%) showed similar results. There were also no significant differences between treatment groups for the secondary outcomes. CONCLUSIONS AND RELEVANCE Empirical macrolide combination therapy conferred no benefit over ß-lactam monotherapy for children hospitalized with community-acquired pneumonia. The results of this study elicit questions about the routine empirical use of macrolide combination therapy in this population.

Original languageEnglish (US)
Pages (from-to)1184-1191
Number of pages8
JournalJAMA Pediatrics
Volume171
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Lactams
Hospitalized Child
Macrolides
Pneumonia
Length of Stay
Therapeutics
Amoxicillin
Clavulanic Acid
Azithromycin
Clarithromycin
Cephalosporins
Ampicillin
Critical Care
Penicillins
Population
Multicenter Studies
Hospitalization
Salts

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Effectiveness of ß-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia. / Williams, Derek J.; Edwards, Kathryn M.; Self, Wesley H.; Zhu, Yuwei; Arnold, Sandra; Mccullers, Jonathan; Ampofo, Krow; Pavia, Andrew T.; Anderson, Evan J.; Hicks, Lauri A.; Bramley, Anna M.; Jain, Seema; Grijalva, Carlos G.

In: JAMA Pediatrics, Vol. 171, No. 12, 01.12.2017, p. 1184-1191.

Research output: Contribution to journalArticle

Williams, DJ, Edwards, KM, Self, WH, Zhu, Y, Arnold, S, Mccullers, J, Ampofo, K, Pavia, AT, Anderson, EJ, Hicks, LA, Bramley, AM, Jain, S & Grijalva, CG 2017, 'Effectiveness of ß-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia', JAMA Pediatrics, vol. 171, no. 12, pp. 1184-1191. https://doi.org/10.1001/jamapediatrics.2017.3225
Williams, Derek J. ; Edwards, Kathryn M. ; Self, Wesley H. ; Zhu, Yuwei ; Arnold, Sandra ; Mccullers, Jonathan ; Ampofo, Krow ; Pavia, Andrew T. ; Anderson, Evan J. ; Hicks, Lauri A. ; Bramley, Anna M. ; Jain, Seema ; Grijalva, Carlos G. / Effectiveness of ß-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia. In: JAMA Pediatrics. 2017 ; Vol. 171, No. 12. pp. 1184-1191.
@article{1958c849d51f4b3989a4ca5fc973fcb1,
title = "Effectiveness of {\ss}-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia",
abstract = "IMPORTANCE {\ss}-Lactam monotherapy and {\ss}-lactam plus macrolide combination therapy are both common empirical treatment strategies for children hospitalized with pneumonia, but few studies have evaluated the effectiveness of these 2 treatment approaches. OBJECTIVE To compare the effectiveness of {\ss}-lactam monotherapy vs {\ss}-lactam plus macrolide combination therapy among a cohort of children hospitalized with pneumonia. DESIGN, SETTING, AND PARTICIPANTS We analyzed data from the Etiology of Pneumonia in the Community Study, a multicenter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted from January 1, 2010, to June 30, 2012, in 3 children’s hospitals in Nashville, Tennessee; Memphis, Tennessee; and Salt Lak City, Utah. The study included all children (up to 18 years of age) who were hospitalized with radiographically confirmed pneumonia and who received {\ss}-lactam monotherapy or {\ss}-lactam plus macrolide combination therapy. Data analysis was completed in April 2017. MAIN OUTCOMES AND MEASURES We defined the referent as {\ss}-lactam monotherapy, including exclusive use of an oral or parenteral second- or third-generation cephalosporin, penicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate. Use of a {\ss}-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) served as the comparison group. We modeled the association between these groups and patients’ length of stay using multivariable Cox proportional hazards regression. Covariates included demographic, clinical, and radiographic variables. We further evaluated length of stay in a cohort matched by propensity to receive combination therapy. Logistic regression was used to evaluate secondary outcomes in the unmatched cohort, including intensive care admission, rehospitalizations, and self-reported recovery at follow-up. RESULTS Our study included 1418 children (693 girls and 725 boys) with a median age of 27 months (interquartile range, 12-69 months). This cohort was 60.1{\%} of the 2358 children enrolled in the Etiology of Pneumonia in the Community Study with radiographically confirmed pneumonia in the study period; 1019 (71.9{\%}) received {\ss}-lactam monotherapy and 399 (28.1{\%}) received {\ss}-lactam plus macrolide combination therapy. In the unmatched cohort, there was no statistically significant difference in length of hospital stay between children receiving {\ss}-lactam monotherapy and combination therapy (median, 55 vs 59 hours; adjusted hazard ratio, 0.87; 95{\%} CI, 0.74-1.01). The propensity-matched cohort (n = 560, 39.5{\%}) showed similar results. There were also no significant differences between treatment groups for the secondary outcomes. CONCLUSIONS AND RELEVANCE Empirical macrolide combination therapy conferred no benefit over {\ss}-lactam monotherapy for children hospitalized with community-acquired pneumonia. The results of this study elicit questions about the routine empirical use of macrolide combination therapy in this population.",
author = "Williams, {Derek J.} and Edwards, {Kathryn M.} and Self, {Wesley H.} and Yuwei Zhu and Sandra Arnold and Jonathan Mccullers and Krow Ampofo and Pavia, {Andrew T.} and Anderson, {Evan J.} and Hicks, {Lauri A.} and Bramley, {Anna M.} and Seema Jain and Grijalva, {Carlos G.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1001/jamapediatrics.2017.3225",
language = "English (US)",
volume = "171",
pages = "1184--1191",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Effectiveness of ß-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia

AU - Williams, Derek J.

AU - Edwards, Kathryn M.

AU - Self, Wesley H.

AU - Zhu, Yuwei

AU - Arnold, Sandra

AU - Mccullers, Jonathan

AU - Ampofo, Krow

AU - Pavia, Andrew T.

AU - Anderson, Evan J.

AU - Hicks, Lauri A.

AU - Bramley, Anna M.

AU - Jain, Seema

AU - Grijalva, Carlos G.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - IMPORTANCE ß-Lactam monotherapy and ß-lactam plus macrolide combination therapy are both common empirical treatment strategies for children hospitalized with pneumonia, but few studies have evaluated the effectiveness of these 2 treatment approaches. OBJECTIVE To compare the effectiveness of ß-lactam monotherapy vs ß-lactam plus macrolide combination therapy among a cohort of children hospitalized with pneumonia. DESIGN, SETTING, AND PARTICIPANTS We analyzed data from the Etiology of Pneumonia in the Community Study, a multicenter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted from January 1, 2010, to June 30, 2012, in 3 children’s hospitals in Nashville, Tennessee; Memphis, Tennessee; and Salt Lak City, Utah. The study included all children (up to 18 years of age) who were hospitalized with radiographically confirmed pneumonia and who received ß-lactam monotherapy or ß-lactam plus macrolide combination therapy. Data analysis was completed in April 2017. MAIN OUTCOMES AND MEASURES We defined the referent as ß-lactam monotherapy, including exclusive use of an oral or parenteral second- or third-generation cephalosporin, penicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate. Use of a ß-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) served as the comparison group. We modeled the association between these groups and patients’ length of stay using multivariable Cox proportional hazards regression. Covariates included demographic, clinical, and radiographic variables. We further evaluated length of stay in a cohort matched by propensity to receive combination therapy. Logistic regression was used to evaluate secondary outcomes in the unmatched cohort, including intensive care admission, rehospitalizations, and self-reported recovery at follow-up. RESULTS Our study included 1418 children (693 girls and 725 boys) with a median age of 27 months (interquartile range, 12-69 months). This cohort was 60.1% of the 2358 children enrolled in the Etiology of Pneumonia in the Community Study with radiographically confirmed pneumonia in the study period; 1019 (71.9%) received ß-lactam monotherapy and 399 (28.1%) received ß-lactam plus macrolide combination therapy. In the unmatched cohort, there was no statistically significant difference in length of hospital stay between children receiving ß-lactam monotherapy and combination therapy (median, 55 vs 59 hours; adjusted hazard ratio, 0.87; 95% CI, 0.74-1.01). The propensity-matched cohort (n = 560, 39.5%) showed similar results. There were also no significant differences between treatment groups for the secondary outcomes. CONCLUSIONS AND RELEVANCE Empirical macrolide combination therapy conferred no benefit over ß-lactam monotherapy for children hospitalized with community-acquired pneumonia. The results of this study elicit questions about the routine empirical use of macrolide combination therapy in this population.

AB - IMPORTANCE ß-Lactam monotherapy and ß-lactam plus macrolide combination therapy are both common empirical treatment strategies for children hospitalized with pneumonia, but few studies have evaluated the effectiveness of these 2 treatment approaches. OBJECTIVE To compare the effectiveness of ß-lactam monotherapy vs ß-lactam plus macrolide combination therapy among a cohort of children hospitalized with pneumonia. DESIGN, SETTING, AND PARTICIPANTS We analyzed data from the Etiology of Pneumonia in the Community Study, a multicenter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted from January 1, 2010, to June 30, 2012, in 3 children’s hospitals in Nashville, Tennessee; Memphis, Tennessee; and Salt Lak City, Utah. The study included all children (up to 18 years of age) who were hospitalized with radiographically confirmed pneumonia and who received ß-lactam monotherapy or ß-lactam plus macrolide combination therapy. Data analysis was completed in April 2017. MAIN OUTCOMES AND MEASURES We defined the referent as ß-lactam monotherapy, including exclusive use of an oral or parenteral second- or third-generation cephalosporin, penicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate. Use of a ß-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) served as the comparison group. We modeled the association between these groups and patients’ length of stay using multivariable Cox proportional hazards regression. Covariates included demographic, clinical, and radiographic variables. We further evaluated length of stay in a cohort matched by propensity to receive combination therapy. Logistic regression was used to evaluate secondary outcomes in the unmatched cohort, including intensive care admission, rehospitalizations, and self-reported recovery at follow-up. RESULTS Our study included 1418 children (693 girls and 725 boys) with a median age of 27 months (interquartile range, 12-69 months). This cohort was 60.1% of the 2358 children enrolled in the Etiology of Pneumonia in the Community Study with radiographically confirmed pneumonia in the study period; 1019 (71.9%) received ß-lactam monotherapy and 399 (28.1%) received ß-lactam plus macrolide combination therapy. In the unmatched cohort, there was no statistically significant difference in length of hospital stay between children receiving ß-lactam monotherapy and combination therapy (median, 55 vs 59 hours; adjusted hazard ratio, 0.87; 95% CI, 0.74-1.01). The propensity-matched cohort (n = 560, 39.5%) showed similar results. There were also no significant differences between treatment groups for the secondary outcomes. CONCLUSIONS AND RELEVANCE Empirical macrolide combination therapy conferred no benefit over ß-lactam monotherapy for children hospitalized with community-acquired pneumonia. The results of this study elicit questions about the routine empirical use of macrolide combination therapy in this population.

UR - http://www.scopus.com/inward/record.url?scp=85038262613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038262613&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2017.3225

DO - 10.1001/jamapediatrics.2017.3225

M3 - Article

VL - 171

SP - 1184

EP - 1191

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 12

ER -